AstraZeneca's Alexion bet continues to pay off as danicopan improves hemoglobin levels in phase 3

AstraZeneca’s $39 billion acquisition of Alexion last year continues to look like money well spent. The latest good news is that the oral factor D inhibitor danicopan can improve hemoglobin levels when added to the approved drugs Ultomiris or Soliris.